LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 160 participants.
Also called NCT07645300
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 160 participants
- Registry
-
NCT07645300
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07645300. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-01 (anticipated); primary completion 2032-03-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial
- Acronym
- LODESTAR
- Condition
- Hypertension Treated With Antihypertensive Drugs
- Condition
- Chronic Kidney Disease, 3B and 4
- Intervention (Drug)
- phase 2A Chlorthalidone
- Intervention (Drug)
- phase 2A Spironolactone
- Intervention (Drug)
- phase 2A Chlorthalidone + Spironolactone
- Intervention (Drug)
- phase 2B Chlorthalidone LD + Spironolactone LD
- Lead sponsor
- VA Office of Research and Development
- Collaborator
- Michael E. DeBakey VA Medical Center
- Collaborator
- VA Salt Lake City Health Care System
Record details
- Record id
cardio:ct-nct07645300- Content hash
a722f9c02b502df51e143bbe7f4a51fb2c8c3da4838f67c3215608d1ef2e74db